Amneal Pharmaceuticals (AMRX) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Amneal Pharmaceuticals (AMRX) over the past year, gaining 125.8% versus a gain of 76.7%. Over five years, KNSA leads with a +706.0% price change compared with +396.9% for AMRX. Kiniksa Pharmaceuticals International is the larger company by market cap ($7.38 billion vs $7.36 billion), about 1.0 times the size.
On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (17.1x vs 45.9x for Kiniksa Pharmaceuticals International). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | KNSA |
|---|---|---|
| Share price | $21.12 | $93.90 |
| Market cap | $7.36B | $7.38B |
| 1-day change | -1.26% | +0.38% |
| YTD return | +67.62% | +127.62% |
| 1-year return | +76.74% | +125.82% |
| 5-year return | +396.94% | +705.97% |
| P/E ratio (TTM) | 52.80 | 71.13 |
| Forward P/E | 17.13 | 45.91 |
| EPS (TTM) | $0.40 | $1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $677.56M |
| Revenue growth (YoY) | +8.05% | +60.09% |
| Net income (latest FY) | $72.06M | $59.01M |
| Gross margin | 36.88% | 88.54% |
| Operating margin | 13.05% | 11.40% |
| Net margin | 2.39% | 8.71% |
| 52-week high | $22.13 | $99.31 |
| 52-week low | $11.71 | $37.02 |
| Distance from 52-week high | -4.54% | -5.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.01% | +18.82% |
| Average volume | 3.16M | 664.53K |
| Shares outstanding | 348.41M | 48.84M |
| Employees | 8,700 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed AMRX by 49.1 percentage points over the past year.
- Kiniksa Pharmaceuticals International trades at a higher earnings multiple (71.1x vs 52.8x trailing P/E).
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus 2.4 cents for Amneal Pharmaceuticals.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +8.05%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
AMRX vs KNSA FAQ
Which is bigger, Amneal Pharmaceuticals or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $7.38B compared with $7.36B for Amneal Pharmaceuticals (AMRX).
Which stock has performed better over the past year, AMRX or KNSA?
KNSA returned +125.82% over the past 12 months, compared with +76.74% for AMRX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMRX or KNSA?
AMRX has the lower trailing P/E at 52.8, versus 71.1 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Amneal Pharmaceuticals and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.